In addition, therapeutic strategies targeting B cells and plasma cells—such as anti‐CD19 CAR‐T cells [202, 203], belimumab (anti‐BAFF) [204], and daratumumab (anti‐CD38 plasma cells) [205]—have shown encouraging results in clinical trials, underscoring the therapeutic potential of B cell‐directed interventions in DM. Here, CD38 is linked to dermatomyositis.